Company: PMVP
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001140361-25-015610
Chunk: 22

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 22
---
 other matters, our audit committee also:

| • | selects and hires the independent registered public accounting firm to audit our financial statements; |

| • | helps to ensure the independence and performance of the independent registered public accounting firm; |

| • | approves audit and non-audit services and fees; |

| • | reviews financial statements and discuss with management and the independent registered public accounting firm our annual audited and quarterly financial statements, the results of the independent audit and the quarterly reviews and the reports and certifications regarding internal controls over financial reporting and disclosure controls; |

| • | prepares the audit committee report that the SEC requires to be included in our annual proxy statement; |

| • | reviews reports and communications from the independent registered public accounting firm; |

| • | reviews the adequacy and effectiveness of our internal controls and disclosure controls and procedure; |

| • | reviews our policies on risk assessment and risk management; |

| • | reviews and monitors conflict of interest situations, and approves or prohibits any involvement in matters that may involve a conflict of interest or taking of a corporate opportunity; |

| • | reviews related person transactions; and |

| • | establishes and oversees procedures for the receipt, retention and treatment of accounting related complaints and the confidential submission by our employees of concerns regarding questionable accounting or auditing matters. |

The audit committee operates under a written charter that satisfies the applicable rules of the SEC and Nasdaq listing rules. Our audit committee’s written charter may be located on our website at ir.pmvpharma.com. The audit committee met five times in fiscal year 2024. Compensation Committee The compensation committee consists of Dr. Heyman, Ms. Stelzer and Dr. Baum, each of whom meets the requirements for independence under current Nasdaq listing standards and SEC rules and regulations. Dr. Heyman is the chairperson of the compensation committee. Each member of the compensation committee is also a non-employee director, as defined pursuant to Rule 16b-3 promulgated under the Exchange Act. The compensation committee oversees our compensation policies, plans and benefits programs. Our compensation committee also:

| • | oversees our overall compensation philosophy and compensation policies, plans and benefits programs; |

| • | reviews and approves, or recommends to the board of directors for approval, compensation for our executive officers and directors; |

12

TABLE OF CONTENTS

| • | prepares the compensation committee report that the SEC will require to be included in our annual proxy statement; and |

| • | admin